Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | fatty acid synthase | 0.0024 | 0.0884 | 0.0736 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0024 | 0.0909 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0185 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.2281 | 0.2156 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0185 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1838 | 0.1705 |
Mycobacterium tuberculosis | Polyketide synthase Pks13 | 0.0036 | 0.1583 | 1 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks5 | 0.0024 | 0.086 | 0.5436 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsA | 0.002 | 0.0634 | 0.172 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.0909 | 0.0761 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0024 | 0.0909 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.0399 | 0.0243 |
Schistosoma mansoni | tar DNA-binding protein | 0.0185 | 1 | 1 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsD | 0.0024 | 0.0903 | 0.4065 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0049 | 0.2281 | 0.1961 |
Echinococcus granulosus | GPCR family 2 | 0.0015 | 0.0399 | 0.0256 |
Toxoplasma gondii | type I fatty acid synthase, putative | 0.0026 | 0.0988 | 1 |
Onchocerca volvulus | Fatty acid synthase homolog | 0.0044 | 0.2006 | 1 |
Mycobacterium leprae | PROBABLE THIOESTERASE TESA | 0.002 | 0.0673 | 0.2064 |
Schistosoma mansoni | hypothetical protein | 0.0015 | 0.0399 | 0.0256 |
Brugia malayi | oxidoreductase, zinc-binding dehydrogenase family protein | 0.0046 | 0.2134 | 0.1807 |
Mycobacterium ulcerans | polyketide synthase Pks13 | 0.0036 | 0.1583 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0024 | 0.0909 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0014 | 0.0298 | 0.014 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsD | 0.0024 | 0.0903 | 0.5702 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0116 | 0.6123 | 0.606 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks15 | 0.001 | 0.0083 | 0.0527 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks9 | 0.0014 | 0.0309 | 0.1953 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsB | 0.002 | 0.0634 | 0.172 |
Echinococcus multilocularis | tar DNA binding protein | 0.0185 | 1 | 1 |
Mycobacterium tuberculosis | Polyketide synthase Pks12 | 0.0026 | 0.0988 | 0.6242 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSB | 0.002 | 0.0634 | 0.172 |
Onchocerca volvulus | 0.0042 | 0.1921 | 0.9285 | |
Brugia malayi | Beta-ketoacyl synthase, N-terminal domain containing protein | 0.0024 | 0.0903 | 0.0525 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0015 | 0.0399 | 0.0256 |
Mycobacterium leprae | Probable multifunctional mycocerosic acid synthase membrane associated enzyme Mas | 0.0026 | 0.0988 | 0.481 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks1 | 0.0017 | 0.0515 | 0.3255 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsC | 0.0024 | 0.0903 | 0.5702 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0024 | 0.0909 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0185 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0185 | 1 | 1 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsA | 0.0024 | 0.0903 | 0.5702 |
Loa Loa (eye worm) | AMP-binding enzyme family protein | 0.0023 | 0.0812 | 0.0663 |
Brugia malayi | hypothetical protein | 0.0016 | 0.0419 | 0.0021 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0015 | 0.0399 | 0.0256 |
Mycobacterium ulcerans | thioesterase TesA | 0.002 | 0.0673 | 0.2064 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0116 | 0.6123 | 0.606 |
Toxoplasma gondii | beta-ketoacyl synthase, N-terminal domain-containing protein | 0.0016 | 0.0419 | 0.2574 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0024 | 0.0909 | 0.5 |
Mycobacterium tuberculosis | Polyketide synthase Pks2 | 0.0024 | 0.086 | 0.5436 |
Mycobacterium tuberculosis | Probable thioesterase TesA | 0.002 | 0.0673 | 0.4254 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.141 | 0.1271 |
Brugia malayi | MH2 domain containing protein | 0.0116 | 0.6123 | 0.5962 |
Mycobacterium ulcerans | polyketide synthase | 0.0026 | 0.0988 | 0.481 |
Mycobacterium tuberculosis | Probable multifunctional mycocerosic acid synthase membrane-associated Mas | 0.0026 | 0.0988 | 0.6242 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSD | 0.0024 | 0.0903 | 0.4065 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0024 | 0.0909 | 0.5 |
Mycobacterium leprae | Probable polyketide synthase Pks1 | 0.0026 | 0.0988 | 0.481 |
Brugia malayi | TAR-binding protein | 0.0185 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0024 | 0.0909 | 0.5 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsC | 0.0026 | 0.0988 | 0.481 |
Schistosoma mansoni | tar DNA-binding protein | 0.0185 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0185 | 1 | 1 |
Mycobacterium ulcerans | thioesterase | 0.002 | 0.0673 | 0.2064 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0033 | 0.141 | 0.1053 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0024 | 0.0903 | 0.4065 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks7 | 0.0026 | 0.0988 | 0.6242 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0015 | 0.0399 | 0.0243 |
Schistosoma mansoni | hypothetical protein | 0.0015 | 0.0399 | 0.0256 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0015 | 0.0399 | 0.0256 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSA | 0.0024 | 0.0903 | 0.4065 |
Mycobacterium ulcerans | polyketide synthase | 0.0024 | 0.0903 | 0.4065 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0024 | 0.0903 | 0.4065 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0049 | 0.2281 | 0.1961 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSC | 0.0026 | 0.0988 | 0.481 |
Schistosoma mansoni | tar DNA-binding protein | 0.0185 | 1 | 1 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks8 | 0.002 | 0.0652 | 0.4119 |
Mycobacterium leprae | Polyketide synthase Pks13 | 0.0036 | 0.1583 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0033 | 0.141 | 0.1282 |
Echinococcus multilocularis | GPCR, family 2 | 0.0015 | 0.0399 | 0.0256 |
Schistosoma mansoni | tar DNA-binding protein | 0.0185 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0015 | 0.0399 | 0.0256 |
Brugia malayi | hypothetical protein | 0.0024 | 0.0909 | 0.0531 |
Mycobacterium ulcerans | multifunctional mycocerosic acid synthase membrane-associated Mas | 0.0026 | 0.0988 | 0.481 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0049 | 0.2281 | 0.2156 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0015 | 0.0399 | 0.0256 |
Mycobacterium tuberculosis | Probable membrane bound polyketide synthase Pks6 | 0.0036 | 0.1583 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0185 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0015 | 0.0399 | 0.0256 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0024 | 0.0903 | 0.4065 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0024 | 0.0909 | 0.8964 |
Toxoplasma gondii | type I fatty acid synthase, putative | 0.0017 | 0.0506 | 0.3708 |
Brugia malayi | AMP-binding enzyme family protein | 0.0023 | 0.0812 | 0.0431 |
Mycobacterium tuberculosis | Phenyloxazoline synthase MbtB (phenyloxazoline synthetase) | 0.0023 | 0.0812 | 0.5131 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 36.8 uM | Indirect antitumour effect was measured as cytotoxicity with human monocytes pretreated with compounds | ChEMBL. | 12904070 |
IC50 (functional) | = 238.6 uM | Indirect antitumour effect was measured as cytotoxicity with murine macrophages pretreated with compounds | ChEMBL. | 12904070 |
IC50 (functional) | = 238.6 uM | Indirect antitumour effect was measured as cytotoxicity with murine macrophages pretreated with compounds | ChEMBL. | 12904070 |
IC50 (functional) | = 534.2 uM | In vitro cytotoxicity against the selected tumour cell line LoVoS arising from human colon adenocarcinoma was determined | ChEMBL. | 12904070 |
IC50 (functional) | = 534.2 uM | In vitro cytotoxicity against the selected tumour cell line LoVoS arising from human colon adenocarcinoma was determined | ChEMBL. | 12904070 |
ND (functional) | 0 | In vitro cytotoxicity against the selected tumour cell line LoVoR arising from human colon adenocarcinoma was determined; not detected | ChEMBL. | 12904070 |
ND (functional) | 0 | Direct cytotoxicity against the selected tumour cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected | ChEMBL. | 12904070 |
ND (functional) | 0 | Direct cytotoxicity against the selected tumour cell line c13* was determined especially on ovarian adenocarcinoma derived cells; not detected | ChEMBL. | 12904070 |
Potency ratio (functional) | = 1 | Potency ratio was determined against LoVoS versus FAA (Flavone acetic acid) | ChEMBL. | 12904070 |
Potency ratio (functional) | = 1.2 | Potency ratio was determined against murine macrophages versus FAA (Flavone acetic acid) | ChEMBL. | 12904070 |
Potency ratio (functional) | = 3.7 | Potency ratio was determined against human monocytes versus DMXAA (Dimethylxanthenone-4-acetic acid); more potent | ChEMBL. | 12904070 |
Potency ratio (functional) | = 6.5 | Potency ratio was determined against macrophages; more potent | ChEMBL. | 12904070 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.